CEO's On the Move
Orvana Minerals Corp. Appoints Michael Winship as President and CEO
Orvana Minerals Corp.
:TSX) Orvana Minerals Corp. announced that Michael Winship has been appointed as President and Chief Executive Officer. Michael has over 30 years' experience in mine development, operations, and corporate business. He has over 30 years of international experience in the operation or development of over 20 ...
Upcoming Board Meetings
December 4, 2013
CSU Cardsystem S.A., Board Meeting, Dec 04, 2013.
CSU Cardsystem S.A. Key Board Members
Chairman, Chief Executive Officer and Member of Executive Board
Chief Financial Officer, Chief Legal Officer, Chief Human Resource Officer, Administr...
SCA Announces Management Changes
SCA's CFO and Executive Vice President Lennart Persson will retire on July 1, 2014, after contributing to SCA's growth in a number of senior positions since 1987. Fredrik Rystedt, 49, will succeed Lennart Persson. Fredrik will become a member of SCA's Corporate Senior Management Team and will be employed from March 1, although he will formally assume his position on July 1, 2014. Fredrik Rystedt has extensive experience of the chief financial officer position gained at a number of listed companies. From 2008 until early 2013, he was the CFO, Executive Vice President and country manager for Sweden for the Nordic banking group Nordea. In his new role at SCA, Fredrik Rystedt will report to President and CEO Jan Johansson.
City of London Group plc Announces Management Changes
City of London Group plc announced that Bruce Mee will be appointed as a Non-Executive Director of COLG with effect from the date of the Placing proceeds being placed into escrow and will be appointed Chief Executive Officer with effect from Completion. John Kent will remain as acting Chief Executive until Completion and will then continue to serve in a consultancy role thereafter.
Yamo Deniz Proposes to Join Cytos Biotechnology AG Board of Directors
Cytos Biotechnology Ltd. announced that Dr. Yamo Deniz is proposed to join Cytos' Board of Directors. Dr. Deniz played a key role in the filing and approval of multiple drugs and in-vivo diagnostics agents in several therapeutic areas of unmet need, including omalizumab (Xolair(R)) for the treatment of asthma in the US and the EU. His extensive experience in the clinical development of asthma products further strengthens Cytos' Board of Directors. Yamo Deniz, MD, currently serves as Chief Medical Officer, Global Head of Medical & Pharmacovigilance at GE Healthcare Lifesciences. Prior to joining GEHC in 2010, Dr. Deniz held numerous senior clinical and leadership positions of increasing responsibilities in respiratory as well as inflammation groups at Genentech and Roche, respectively. Dr. Deniz played a key role in the filing and approval of multiple drugs and in-vivo diagnostics agents in several therapeutic areas of unmet need, including omalizumab (Xolair(R)) for the treatment of asthma in the US and the EU.
Top Compensated Executives at ORV:CN
|Chief Financial Officer|
|Chief Operating Officer|
|Compensation as of Fiscal Year 2012. All Compensation is in USD.|
Average Compensation in the Metals and Mining Industry
|Metals and Mining||$280.8K|
|Diversified Metals and Mining||$263.6K|
|Precious Metals and Minerals||$237.5K|